Karen Jagoda’s Post

#podcast Phil Johnston, President & CEO of Johnston Associates, and an advisor to EO Care, the market leader in providing clinically-guided cannabis use. Phil discusses the potential for research from the reclassification of cannabis from a Schedule I drug to a Schedule III drug.  With current Federal restrictions on cannabis, research has not been conducted on the potential therapeutic use for pain relief, depression, PTSD, & other conditions. With a change in classification, researchers can develop protocols, test different cannabis strains, run clinical trials, & determine dosage and form for therapies.   #MedicalCannabisClinicalResearch #CannabisRescheduling PWJohnston.com EOCare.com https://lnkd.in/gJ227Ep3

Empowered Patient Podcast: Research Set to Expand as Federal Government Considers Rescheduling Cannabis from Schedule I to Schedule III with Phil Johnston Johnston Associates

Empowered Patient Podcast: Research Set to Expand as Federal Government Considers Rescheduling Cannabis from Schedule I to Schedule III with Phil Johnston Johnston Associates

empoweredpatientradio.com

To view or add a comment, sign in

Explore topics